Clinical Trial Update: Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing the efficacy and safety of fluticasone propionate/salmeterol xinafoate delivered via an HFA MDI in pediatric asthma. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Fluticasone propionate / salmeterol xinafoate inhalation aerosol (HFA) (fluticasone propionate / salmeterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 4 | Status: COMPLETED | Results posted: 2017-06-16